Drug intelligence / Profile preview

BD03

Development stage: Phase 1
Lead developer: SL VaxiGen
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

BD03 is a DNA vaccine developed by SL VAXiGEN. It is designed for the prevention of Cytomegalovirus (CMV) and BK virus (BKV) reactivation in kidney transplant recipients. The vaccine is administered intramuscularly and is currently in a Phase 1 clinical trial to evaluate its tolerability and safety and to determine the recommended Phase 2 dose.

Targets

AIM2 (Absent in melanoma 2)STING (Stimulator of interferon genes protein)TLR9 (Toll-like receptor 9)Cyclic GMP–AMP synthase

Beyond the preview

Go deeper on BD03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BD03.